MicroPort Scientific (HK:0853) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
MicroPort Scientific’s subsidiary, Shanghai MicroPort Endovascular MedTech, reported a significant financial performance for the first nine months of 2024, with a 9.13% increase in revenue and a 40.82% rise in profit compared to the same period last year. The net profit attributable to equity owners surged by 42.46%, indicating strong growth potential for investors. Despite the impressive results, investors are advised to consider these figures cautiously as they offer a limited view of the company’s overall operations.
For further insights into HK:0853 stock, check out TipRanks’ Stock Analysis page.
